Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 20, 2021, covers material events for Jazz Pharmaceuticals Plc. The filing primarily addresses the entry into a material definitive agreement to amend its credit facilities and provides preliminary unaudited estimated financial results for the three months ended March 31, 2021. The company is also in the process of acquiring GW Pharmaceuticals PLC, with closing expected in the first half of May 2021.
Key Financial Metrics (Q1 2021 Estimates)
The following figures represent preliminary unaudited estimates provided by management and are subject to change upon final audit.
| Metric | Q1 2021 Estimate | Q1 2020 Actual |
|---|---|---|
| Revenues | $605 million - $610 million | $535 million |
| GAAP Net Income | $120 million - $124 million | ($158 million) Loss |
| Adjusted EBITDA | $303 million - $307 million | $250 million |
| Cash, Cash Equivalents & Investments | $2.4 billion (as of March 31, 2021) | $2.1 billion (as of Dec 31, 2020) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased approximately 13% to 14% year-over-year. This growth is primarily driven by the inclusion of revenues from Xywav and Zepzelca following their 2020 launches, partially offset by a reduction in Xyrem revenues as patients transition to Xywav.
- Profitability Turnaround: The company moved from a GAAP net loss of $158 million in Q1 2020 to an estimated net income of $120 million to $124 million in Q1 2021.
- Adjusted EBITDA: Adjusted EBITDA increased by approximately 21% to 23% compared to the prior year period.
- Liquidity: Cash and investments increased by $0.3 billion from the end of 2020 to March 31, 2021.
Guidance, Outlook, and Material Events
- GW Pharmaceuticals Acquisition: Jazz expects to consummate the acquisition of GW Pharmaceuticals PLC in the first half of May 2021, subject to shareholder approvals and other closing conditions.
- Financing and Debt: On April 20, 2021, Jazz entered into Amendment No. 3 to its Credit Agreement to permit the issuance of senior secured notes. The company plans to refinance its existing credit agreement with new senior secured facilities in connection with the GW acquisition.
- Offering of Notes: Jazz Securities Designated Activity Company, a wholly-owned subsidiary, is launching a private offering of senior secured notes to support the acquisition.
- Risks and Contingencies: Forward-looking statements are subject to risks including the ability to complete the acquisition, regulatory approvals, integration challenges, and the impact of the COVID-19 pandemic on operations and sales.
Investor Verification Checklist
- Verify the final audited Q1 2021 financial results against these preliminary estimates.
- Confirm the successful closing of the GW Pharmaceuticals acquisition and the associated financing terms.
- Monitor the transition of patients from Xyrem to Xywav and its impact on future revenue stability.
- Review the definitive proxy statement for GW Pharmaceuticals regarding shareholder approval status.
- Assess the terms of the new senior secured notes and the refinancing of the existing credit agreement.